Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.

Therapeutic advances in respiratory disease - 1 Jan 2025

Terlizzi Vito, Lopes-Pacheco Miquéias

Abstract excerpt

Over the past decade, major clinical advances have been made in the healthcare and therapeutic development for cystic fibrosis (CF), a lethal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. CFTR modulators represent innovative treatments that directly target the primary defects in the mutated CFTR protein and have demonstrated significant...

Topics

Join the communities discussing this publication.

Aminophenols
Benzodioxoles
Chloride Channel Agonists
Drug Interactions
Pyrazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 40163448
DOI: 10.1177/17534666251323194
PMCID: PMC11960163

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.PMID 40163448Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.Semantic proximity Read ↗

Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity Read ↗

Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges.Semantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations.Semantic proximity Read ↗

Tezacaftor for the treatment of cystic fibrosis.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study.Semantic proximity Read ↗

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.Semantic proximity Read ↗

Precision Medicine Based on CFTR Genotype for People with Cystic FibrosisSemantic proximity Read ↗

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Semantic proximity Read ↗

Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.